Factorial design-based development of measlamine microspheres for colonic delivery.

Biomatter Pub Date : 2011-10-01 DOI:10.4161/biom.18461
Vikas Jain, Dayal Prasad, Deepika Jain, Santosh Kumar Mishra, Ranjit Singh
{"title":"Factorial design-based development of measlamine microspheres for colonic delivery.","authors":"Vikas Jain,&nbsp;Dayal Prasad,&nbsp;Deepika Jain,&nbsp;Santosh Kumar Mishra,&nbsp;Ranjit Singh","doi":"10.4161/biom.18461","DOIUrl":null,"url":null,"abstract":"<p><p>For treating colonic diseases, conventional oral drug delivery systems are not effective, as they fail to reach the appropriate site of action. Thus, there is a need to develop effective and safe therapy for the treatment of colonic disorders. The aim of the present study was to design a colon-specific delivery system for an anti-inflammatory drug, mesalamine, with minimal degradation and optimum delivery of the drug with relatively higher local concentration, which may provide more effective therapy for inflammatory bowel disease including Crohn disease and ulcerative colitis. Factorial designs (four factors and two levels) for eudragit S-100 (pH-dependent polymer)-coated, pectin (natural polysaccharides)-based microspheres of mesalamine were constructed and conducted in a fully randomized manner to study all possible combinations. Based on the desirability function formulation, F14 was found to be the best formulation. The overall desirability coefficient of formulation F14 was found to be 0.825. The formulation F14 was subjected to in vitro release studies, and the results were evaluated kinetically and statistically. The microspheres started releasing the drug at the beginning of 7th hour, which corresponds to the arrival time at proximal colon. The cumulative percent drug release for formulation F14 at the end of 16 h was found to be 98%. The release kinetics showed that the release followed the Higuchi model, and the main mechanism of drug release was diffusion. The study presents a new approach for colon-specific drug delivery.</p>","PeriodicalId":8891,"journal":{"name":"Biomatter","volume":"1 2","pages":"182-8"},"PeriodicalIF":0.0000,"publicationDate":"2011-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4161/biom.18461","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomatter","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4161/biom.18461","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

For treating colonic diseases, conventional oral drug delivery systems are not effective, as they fail to reach the appropriate site of action. Thus, there is a need to develop effective and safe therapy for the treatment of colonic disorders. The aim of the present study was to design a colon-specific delivery system for an anti-inflammatory drug, mesalamine, with minimal degradation and optimum delivery of the drug with relatively higher local concentration, which may provide more effective therapy for inflammatory bowel disease including Crohn disease and ulcerative colitis. Factorial designs (four factors and two levels) for eudragit S-100 (pH-dependent polymer)-coated, pectin (natural polysaccharides)-based microspheres of mesalamine were constructed and conducted in a fully randomized manner to study all possible combinations. Based on the desirability function formulation, F14 was found to be the best formulation. The overall desirability coefficient of formulation F14 was found to be 0.825. The formulation F14 was subjected to in vitro release studies, and the results were evaluated kinetically and statistically. The microspheres started releasing the drug at the beginning of 7th hour, which corresponds to the arrival time at proximal colon. The cumulative percent drug release for formulation F14 at the end of 16 h was found to be 98%. The release kinetics showed that the release followed the Higuchi model, and the main mechanism of drug release was diffusion. The study presents a new approach for colon-specific drug delivery.

Abstract Image

Abstract Image

Abstract Image

基于因子设计的甲胺微球结肠给药研究。
对于治疗结肠疾病,传统的口服给药系统是无效的,因为它们不能到达适当的作用部位。因此,有必要开发有效和安全的治疗结肠疾病的方法。本研究的目的是设计一种消炎药美沙拉胺的结肠特异性递送系统,以最小的降解和相对较高的局部浓度的最佳递送药物,这可能为包括克罗恩病和溃疡性结肠炎在内的炎症性肠病提供更有效的治疗。构建了四因素两水平的析因设计(四因素两水平),对桉木糖S-100 (ph依赖性聚合物)包被,果胶(天然多糖)为基础的美沙拉胺微球进行了完全随机的设计,以研究所有可能的组合。根据期望函数公式,确定F14为最佳配方。配方F14的总体理想系数为0.825。对制剂F14进行体外释放实验,并对实验结果进行动力学和统计学评价。微球在第7小时开始释放药物,这与到达近端结肠的时间相对应。F14制剂16 h的累积释药率为98%。释放动力学表明,该药物的释放符合Higuchi模型,其主要释放机制为扩散。本研究提出了一种结肠特异性给药的新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信